Shanghai Microport Medical (Group) Co., Ltd. (Microport Robot) announced the unaudited interim performance for the six months ended June 30, 2024. During the period, the company's revenue reached RMB 99.2 million, an increase of 108.5% compared to the same period last year. Gross profit also increased from RMB 22.1 million to RMB 47.0 million. However, the company recorded a net loss of RMB 280.0 million, although this is an improvement compared to the RMB 544.7 million loss in the same period last year. The revenue growth is mainly attributed to the increasing sales of the core product Tummy Observe Surgery Robot in both domestic and international markets, as well as the doubling of sales volume of Honghu Orthopedic Surgery Robot. The company continues to implement strategic focus...Show More

Shanghai Microport Medical (Group) Co., Ltd. (Microport Robot) announced the unaudited interim performance for the six months ended June 30, 2024. During the period, the company's revenue reached RMB 99.2 million, an increase of 108.5% compared to the same period last year. Gross profit also increased from RMB 22.1 million to RMB 47.0 million. However, the company recorded a net loss of RMB 280.0 million, although this is an improvement compared to the RMB 544.7 million loss in the same period last year. The revenue growth is mainly attributed to the increasing sales of the core product Tummy Observe Surgery Robot in both domestic and international markets, as well as the doubling of sales volume of Honghu Orthopedic Surgery Robot. The company continues to implement strategic focus and cost reduction measures, and the net outflow of free cash flow reduced by 49.7% during the reporting period. In addition, the company completed the placement of new H shares in July 2024, raising approximately HKD 114.8 million in funds, which will be used for product research and development and market expansion in the future.